Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02515214
Other study ID # AURORA
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 2012
Est. completion date January 2025

Study information

Verified date May 2021
Source Universitaire Ziekenhuizen Leuven
Contact Roland Devlieger, MD, PhD
Phone +3216342212
Email roland.devlieger@uzleuven.be
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The use of bariatric surgery has risen subsequently over the last decade, especially in women of reproductive age. (Unplanned) pregnancies in this subgroup are not rare because of e.g. an increased fertility (because of the weight loss) and a possible ineffectiveness of contraceptives (because of a malabsorption in the intestine). Although a pregnancy after bariatric surgery is generally known as safe, there are a few studies that indicate that a pregnancy after a bariatric surgery is not always without complications, and that it should be considered as a high risk pregnancy. The research on pregnancy outcomes after this type of surgery is rather limited to a few small, mainly retrospective, observational case-control and cohort studies and a limited amount of case studies. For risk- and prognose related issues, e.g. the effect of bariatric surgery on fertility, timing of the pregnancy, development of complications during the pregnancy and pregnancy outcomes, large prospective cohort studies are needed. Besides, breast feeding practices and breast milk composition have scarcely been investigated in this population. The energy content of breast milk could possibly be influenced by a state of malabsorption after the procedure. Low amounts of vitamin B12 have also been noticed in the breast milk of women the surgery. The overall objective of this study is to establish a group of women at reproductive age (age 18-45) with a history of bariatric surgery and to generate an extensive database for future analysis. The final goal of the researchers is to develop guidelines or recommendations on how to manage pregnancies after bariatric surgery, based on large-scale prospective research. The study design is a multicentric observational and prospective cohort study. Participants will be followed from the moment of surgery until 6 months postpartum and they can be included on several time points (before surgery, after surgery (<12 months); after surgery (>12 months) or during the pregnancy). Both retrospective and prospective data concerning the medical background, fertility (menstrual cycle), lifestyle (e.a. food, physical activities, smoking, sleeping), blood samples, psychological factors (fear and depression), sexuality, quality of life and pregnancy outcomes will be collected. Data collection by the investigators will happen in a web-based database and by direct online registration by the subjects.


Description:

The investigators aim to develop guidelines or recommendations for the management of pregnancies after bariatric surgery based on large-scale prospective research. The investigators want to: 1. investigate pregnancy outcomes of women with a history of bariatric surgery according to procedure, interval between surgery and conception, weight change after surgery and during pregnancy and nutritional status, taking into account possible confounding factors such as economic status, alcohol and tobacco use, sleep duration, psychological factors (anxiety and depression) and quality of life 2. determine the incidence of nutritional deficiencies in (pregnant) women of reproductive age after bariatric surgery. 3. evaluate the effect of bariatric surgery in (morbidly) obese women of reproductive age on anthropometry, fertility, sexuality, co-morbidities, use of medication and contraceptives, pregnancy outcomes, quality of life, psychological factors (anxiety and depression), blood biochemical parameters (nutritional status), food intake and physical activity 4. examine breastfeeding practices (intention, initiation, duration) and breast milk composition in women with a history of bariatric surgery The study is a multicentric prospective cohort study with UZ Leuven as the coordinating central cite and AZ St Jan Brugge (obesity clinic and obstetric clinic), AZ St Lucas Brugge (obstetric clinic), AZ St Nikolaas St Niklaas (obesity clinic), UZ Gent (obesity clinic and obstetric clinic), AZ St Augustinus Wilrijk (obstetric clinic) and CHRH Mons Hainaut (obesity clinic and obstetric clinic) as local sites. The design for the breast milk analyses is longitudinal and will, for practical reasons, only be initiated in UZ Leuven and UZ Gent. The investogators will collect a breast milk sample of 10 ml on day four of the postpartum and then weekly by the participants at home until the routine 6 week postpartum consultation. Women will be included in one of the following four inclusion moments (IM): - Before surgery (women of reproductive age with morbid obesity) (IM1) - After surgery and not being pregnant (IM2) - Before 15 weeks of gestation (IM3) - Day 3 of 4 of the postpartum for breast milk analyses (IM4) A simple, user-friendly website will be used to simplify the collection and entry of data and to create a large database. Researchers will be able to directly and continuously register patient data (replacing paper forms) and participants will be able to complete the questionnaires online. The database will be available via a secure online login. Participating researchers will only have access to their own patient database. For breast milk analyses, the investigators wil collect a sample of 10 ml during the first feeding moment (between 8 am and 11am) on day four of the postpartum manually or by use of a vacuum pump. Each sample is divided into two different recipients. One part of the sample is frozen immediately in the freezer at -20 °C. The rest of the sample will immediately be heated to +40 °C by use of a bottle warmer. As soon as the sample is heated, it will be ultrasonically analyzed with the MIRIS Sonicator® in order to ensure that the sample is homogeneous. Immediately afterwards, the sample is analyzed with the Human Milk Analyzer (HMA) (MIRIS ®, Uppsala, Sweden) for fat (g/100 ml), proteins (g/100 ml), carbohydrates (g/100 ml), dry matter (g/100 ml) and energy (kcal/100ml). The samples that are being collected at the participants' homes will be frozen at -20° and afterwards analyzed with the HMA. There are eleven measurement points: T0 = baseline T1 = pre-operative T2 = 3 weeks post-operative T3 = 3 months post-operative T4 = 6 months post-operative T5 = 12 of x months post-operative T6 = first trimester pregnancy T7 = second trimester pregnancy T8 = third trimester pregnancy T9 = pregnancy T10 = 6 weeks postpartum T11 = 6 months postpartum The number of measurements varies according to the moment of inclusion. 1. Demographical data will be collected at (T0) (participant self-reporting). Age, nationality, ethnicity, marital status, family status, educational level, employment status and profession wil be questioned. 2. Anthropometric data, including body weight, waist circumference, hip circumference and body fat percentage (if measured) are collected at all measurement points and will be recorded by the researcher. The body length is only questioned at the first measurement. Body height and body weight will be used to calculate the Body Mass Index (kg/m²) at each measurement point. 3. During the first measurement the investigators will ask for past medical conditions (reported by the researcher) and obstetric history (gravidity, parity, abortion - self-report participant); 4. The type of procedure, date of surgery and institute of the surgeon will be recorded by the investigators during the first measurement (Reported by researcher). Potential problems or complications will be reported at the next measurement points. (T1-T5). 5. Current medical conditions (eg hypertension) will be reported at each measurement point, together with the used medication (Reported by the researcher). 6. The nutritional status of the participant will be assessed by the investigators on the basis of biochemical parameters in the venous blood. The nutritional status of the newborn will be assessed on the basis of biochemical parameters in the venous umbilical cord blood. (total protein and albumin, fasten glucose level, fat soluble vitamins A, 25 -hydroxy- vitamin D, vitamin E and vitamin K1, water soluble vitamins B1, vitamin B12 and folate (in the serum and red blood cells (RBC), iron , (+ transferrin, transferrin saturation, ferritin ), calcium, zinc and magnesium, hematology (hemoglobin, hematocrit and RBC count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV)), coagulation (prothrombin time (PT) and activated partial thromboplastin time (aPTT)). During measurement time T1, T3, T4, T5, a blood sample will be taken at the department of endocrinology and on T6, T7, T9 and T10 at the department of obstetrics-gynecology. 7. Investigators will ask the participants about alcohol, tobacco and sleeping habits (self-report participant). The alcohol consumption will be asked by using the AUDIT-C questionnaire (Alcohol Abuse Disorder Identification Test). If the participant smokes, the amount of cigarettes or other tobacco products that are smoked daily will be recorded. At the beginning of pregnancy, the participant will be asked whether alcohol and tobacco use have changed. Finally, the sleep duration will also be determined. 8. The food intake will be measured during three days (of which at least 1 day in the weekend), on the basis of a 3-day food diary (self-report participant). The intake of supplements is also questioned (self-report participant). 9. Physical activity will be measured by use of the Kaiser Physical Activity Survey (KPAS), a modified version of the Baecke physical activity questionnaire, which was specifically designed to assess the physical activity in women. The KPAS assesses different domains of physical activity (household /family care activities, professional activities, activities of daily life and sports/exercise). The KPAS was validated for both pregnant and non-pregnant women. 10. The Moorehead-Ardelt Quality of Life Questionnaire II (MA QoLQII) will be used both pre-and postoperatively to assess the quality of life (self-report participant). This validated questionnaire is part of the Bariatric Analysis and Reporting Outcome System (BAROS). The MA QoLQII has been validated in an obese population and can be used for bariatric surgery. 11. The Self-Rating Questionnaire will be used to assess the psycho-social condition of the participant. This is a Dutch-validated questionnaire to measure anxiety, based on the American "State-Trait Anxiety Inventory" version Y of Spielberger (35). The questionnaire included two separated self- questionnaires in which two different concepts can be measured: state anxiety and trait anxiety. The Edinburgh Depression Scale (EDS), a validated 10-item questionnaire, will be used to measure depression during pregnancy and postpartum (self-report participant). 12. A questionnaire will be used to record the menstrual cycle (self-report participant). The menstrual cycle's length, duration of bleeding, number of periods per year, the pattern of the menstrual cycle and the presence of amenorrhea or oligomenorrhea will be assessed. The questionnaire is administered at T1, T4 and T5. 13. Pregnancy intention is asked in non-pregnant women (self-report participant) at the first measurement point (T0). 14. The use of contraceptives, which also examines the therapy adherence, is also questioned (self-report participant). The questionnaire is administered at T1, T4 and T5. 15. Sexuality will be questioned to determine the relationship with fertility and the interval between surgery and pregnancy (self-report participant). The questionnaire will be completed at T1, T4 and T5. 16. Clinical pregnancy outcomes of the mother will be questioned each pregnancy trimester (T6-T8) (Reported by the researcher) e.g. conception method, blood pressure, gestational age, gestational diabetes, pre-eclampsia, pregnancy-induced hypertension, clinical problems, etc. The results of the fetal ultrasounds will also be collected during each pregnancy trimester (T6-T8). During childbirth (T9) the duration of pregnancy, labor and delivery method will be questioned. The parameters of the newborn, including gender, birth weight, birth length, head circumference, Apgar scores, admission to the neonatal intensive care unit (NICU) and any complication will be recorded (T9). Finally, postpartum data such as hemoglobin, prescribed supplements, breastfeeding, or any other problems will be recorded. 17. A structured questionnaire about breastfeeding practices, developed by Guelinckx et al. (2011), will be used at 6 months postpartum (T11) (self-report participant). This questionnaire consists of 11 questions including the intention to breastfeed, breastfeeding initiation, duration of (exclusive) breastfeeding and the reasons to stop with breastfeeding.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Women will be included in one of the following four inclusion moments (IM): - Before surgery (women of reproductive age with morbid obesity) (IM1) - After surgery and not being pregnant (IM2) - Before 15 weeks of gestation (IM3) - Day 3 of 4 of the postpartum for breast milk analyses (IM4) Inclusion and exclusion criteria: 1. IM1 Inclusion criteria: - Women - Age between 18 and 45 years - planning bariatric surgery Exclusion criteria: - Infertile (eg, hysterectomy, menopause, etc.) 2. IM2 Inclusion criteria: - Women - Age between 18 and 45 years - A bariatric surgery in the past Exclusion criteria: - Infertile (eg, hysterectomy, menopause, etc.) 3. IM3 Inclusion criteria: - Women - Age between 18 and 45 years - A bariatric surgery in the past - <15 weeks pregnant Exclusion criteria: - Recruitment after 15 weeks of gestation 4. IM4 Inclusion criteria: - Women - Age between 18 and 45 years - A bariatric surgery in the past - Gestational age between 37 and 42 weeks - Giving birth of a viable child (singleton) - Breastfeeding on day 3 of the postpartum Exclusion criteria: - Intake of the following drugs during lactation: psychotropic drugs, cytotoxic drugs, beta-blockers, dopamine agonists, aspirin, antihistamines, ergotamine, lithium, phenindione, barbiturates, anticonvulsants and sulfasalazine - Diabetes mellitus or diabetes mellitus gravidarum - Newborn admitted to the NICU (no rooming-in) - Uncertainty if milk production is sufficient to meet the needs of the baby (in consultation with the midwife)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Belgium UZ Leuven Leuven

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Maternal age Maternal age (birth date, age) assessed by online questionnaire baseline
Other Nationality Belgium versus other assessed by online questionnaire baseline
Other Family status Family status (living together with or without children, living seperate, living with parents) assessed by online questionnaire baseline
Other Educational level Educational level (until 18 yr, +18yr high school, +18yr university or higher) assessed by online questionnaire baseline
Other Profession Profession (working full/half time, studying, unemployed) assessed by online questionnaire baseline
Other Marietal status Marietal status (married, living together, in a relation, divorced, widow) assessed by online questionnaire baseline
Other BMI body mass index baseline
Primary Gestational weight gain Weight at birth minus weight at start of pregnancy Birth
Primary Gestational length Preterm (<37w of gestation) vs a term (37-42w of gestation) delivery Birth
Primary Surgical complications during pregnancy bowel obstruction, strangulation, internal herniation up to birth
Primary Gestational diabetes mellitus disturbed glucose metabolism up to birth
Primary Hypertensive disorders pregnancy-induced hypertension, (pre-)eclampsia up to birth
Primary Birth weight Weight of newborn baby (<2.5kg small-for-gestational age; >4kg macrosomia) Birth
Secondary Quality of life assessed by the Moorehead-Ardelt Quality of Life Questinnaire II quality of life assessed by the Moorehead-Ardelt Quality of Life Questinnaire II preoperatively, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6w and 6 mo)
Secondary Breast milk fat content Breast milk fat content assessed by the Human Milk Analyzer weekly from day 3-4 after delivery until week 6 after delivery
Secondary Contraception Pattern and duration of menstrual cycle and contraceptive use assessed by a self-developed questionnaire baseline, postoperatively (6 and 12mo)
Secondary Physical activity Level of physical activity (household, work, free time, sports) assessed by the Kaiser Physical Activity Survey baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)
Secondary Dietary intake Dietary intake assessed by a semi-structured 3 day estimated dietary record method (3 day food diary) baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)
Secondary Sleeping habits sleeping habits (week and week-end) assessed by a self-developed questionnaire baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)
Secondary Breastfeeding practices Assessed by a structured questionnaire by Guelinckx et al. (2011): initiation and duration of breastfeeding, exclusively breastfeeing, artificial feeding Postpartum period (6mo)
Secondary Anxiety State and Trait anxiety assessed by the State-Trait Anxiety Inventory baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 3 (28-32w) and postpartum period (6w and 6 mo)
Secondary Depression depressive feelings assessed by the Edinburgh Postnatal Depression Scale; baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 3 (28-32w) and postpartum period (6w and 6 mo)
Secondary Alcohol use drinking habits assessed by the Alcocol Abuse Disorder Identification Test (AUDIT-c) baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)
Secondary Smoking habits Smoking habits (amount of sigarets, changes during pregnancy) assessed by a self-developed questionnaire baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)
Secondary Sexuality Sexual activity is assessed by a self-developed questionnaire baseline, postoperatively (6 and 12mo)
Secondary Total blood count red blood cells, hematocrit, hemoglobin, MCV, MCH, MCHC assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary Vitamin A Vitamin A serum level assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary 25-OH-vitamin D Vitamin 25-OH-vitamin D serum level assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary vitamin K1 Vitamin K1 serum level assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary Vitamin B-12 Vitamin B12 serum level assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary Folate Folate (serum and red blood cells) assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary Coagulation prothrombin time, activated partial tromboplastin time and coagulation factors assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary Glucose Fasten glucose level assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary Zinc Zinc serum level assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary Anemia Iron, ferritin, transferrin (saturation) levels assessed by venipuncture baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)
Secondary Breast milk protein content Breast milk fat protein assessed by the Human Milk Analyzer weekly from day 3-4 after delivery until week 6 after delivery
Secondary Breast milk carbohydrate content Breast milk carbohydrate content assessed by the Human Milk Analyzer weekly from day 3-4 after delivery until week 6 after delivery
Secondary Breast milk energy content Breast milk energy content assessed by the Human Milk Analyzer weekly from day 3-4 after delivery until week 6 after delivery
Secondary Mode of delivery vaginal, cesarean section, instrumental delivery Birth
Secondary Apgar score Apgar score (appearance, pulse, grimase response, activity, respiration) assessed by the medical staff Birth (2-5-10 minutes)
Secondary Body weight Weight measured by the medical staff to 1) calculate the body mass index and 2) to report weight loss (after surgery) or weight gain (during pregnancy) baseline, post-operatively (3w, 3, 6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w), and 3 (28-32w) and the postpartum period (6w and 6mo)
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Completed NCT02523755 - Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia Phase 4